# AHEAD-MERIT (NCT04534205)

> A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04534205
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: BioNTech SE
- Conditions: Unresectable Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer
- Interventions: BNT113; Pembrolizumab
- Enrollment: 358
- Primary outcome: Part A - Occurrence of treatment-emergent adverse event (TEAE) - BNT113 in combination with pembrolizumab
- Primary outcome: Part B - Overall survival (OS)
- Primary outcome: Part B - Progression-free survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ahead-merit-nct04534205